Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Ad image

Leverage AI to lower drug discovery costs and provide more briefings

MONews
0 Min Read

New AI Hellp.s. cut down the money drug discovery

Australian researchers have created a new drug discovery AI tool to decipher protein-molecule interactions without the need to render costly 3D structures.

The drug discovery model, called PSICHIC (PhySIcoCH

PSICHIC was able to “effectively screen new drug candidates and perform selectivity profiling,” in one study, the results of which were published in Nature Machine Intelligence. According to study co-author Dr Lauren May of the Monash Institute of Pharmaceutical Sciences, it can also distinguish between the “functional effects” of a compound, or the way it affects the body. There was.


Digital Twin for Ventilation Optimization

Researchers at the University of Canterbury are using digital twin technology to optimize mechanical ventilation.

It said it would use a digital twin of patient information, such as the amount of sedation needed, pressure and flow to the lungs, to “predict whether more pressure, volume or oxygen would help the patient gain lung volume without causing damage.” . Geoff Chase, distinguished professor at the University of Canterbury.

A person who needs ventilation will pay twice as much for a day in the ICU. Professor Chase claimed: “Reducing the time on ventilator not only leads to better outcomes for patients, but for New Zealand, saving just one day equates to potential savings of N$17 million ($10 million) per year.”


Novari Continues International Collaboration for Advanced Patient Engagement

Personify Care and Canada-based Novari Health have partnered for integrated services.

Based on press releases, the two companies’ combined solution will enable Novari’s referral management software to initiate clinically defined rehabilitation and pre-admission pathways.

Through the partnership, Novari Patient Engage, powered by PersonifyCare, will be launched in Canada and the UK, and the companies’ “fully interoperable products” will be rolled out across Australia and New Zealand.

In March Novari Health has also partnered with Australian company Alcidion to provide integrated solutions to improve patient flow management.

Share This Article